CJC-1295 research guide for Tsovasar. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Research-Grade CJC-1295 for Tsovasar Investigators
Most researchers trying to source CJC-1295 in Tsovasar quickly find that local retail options are virtually absent. The practical takeaway for Tsovasar researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the framework for evaluating that quality is universal across all locations. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Tsovasar researchers need to know about purchasing, testing, and working with CJC-1295 for research purposes.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Tsovasar studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
The most consistent path to quality CJC-1295 is community research first — peptide forums aggregate real purchasing experience that are more trustworthy than marketing materials. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone does not confirm what the compound actually is. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, unclear production details, no community presence, and COAs that lack endotoxin data. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Tsovasar
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
